Physician profile
Andrej Petrov
NPI 1538134069
$73,715.96
in general payments reported to CMS, 2019-2025
18 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,129 · 2020: $11K · 2021: $14.40 · 2022: $3,138 · 2023: $11K · 2024: $12K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Food and Beverage: $6,389 · Honoraria: $4,770 · Travel and Lodging: $4,288 · Education: $47.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,440.72 |
| Food and Beverage | $6,388.89 |
| Honoraria | $4,770.00 |
| Travel and Lodging | $4,287.62 |
| Education | $47.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $31,680.71 | 2024-2025 | Ebglyss |
| Genentech USA, INC. | $9,523.59 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $8,004.53 | 2019-2024 | Nucala |
| Blueprint Medicines Corporation | $7,785.04 | 2022-2024 | Ayvakit |
| Csl Behring | $7,357.52 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pharming Healthcare, INC. | $3,333.49 | 2020-2024 | Ruconest |
| Genzyme Corporation | $1,825.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,375.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,073.03 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Novartis Pharmaceuticals Corporation | $486.43 | 2024-2025 | |
| Grifols USA, LLC | $430.98 | 2022-2024 | Xembify |
| Shire North American Group INC | $232.13 | 2019 | |
| Aquestive Therapeutics, INC. | $152.67 | 2025 | |
| Optinose US, INC. | $127.11 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $121.06 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $106.26 | 2025 | Brinsupri |
| Regeneron Pharmaceuticals, INC. | $101.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrej Petrov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.